For Q122, US Joint Fluid Replacement market players continued on a running growth, which did not seem too disrupted by the COVID Omicron variant. Furthermore, some players shared that despite physicians’ offices not yet running at 100% levels, company sales representatives were able to hold face-to-face visits and secure new orders.
Among the many topics covered in detail in our comprehensive Q122 US Joint Fluid Replacement Market Recap* are:
For the first quarter of 2022, the US Viscosupplementation Market achieved increased vs Q121, according to SmartTRAK Financial Dashboard. Positive aggregate revenue performance was credited to a very solid quarter for each of the US Viscosupplementation segments, with all but one experiencing double-digit growth. On a sequential basis, although the total revenue was ...
*The entire unedited article and these links can only be viewed by SmartTRAK subscribers to this module. For more information on SmartTRAK, including how to receive a demo and subscribe, please click the button below.